Systematic Review And Meta-Analysis Of Psoriasis Treatments.

Pfizer

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT01425138

A3921142

Details and patient eligibility

About

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.

Full description

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
• Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion criteria

Observational studies

• Trials that did not report the Physician's Global Assessment (PGA),
• Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).

Trial design

1 participants in 1 patient group

Psoriasis

Description:

Published data on moderate-to-severe plaque psoriasis.